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Abstract
Aim: SOX4, as a member of the SRY-related HMG-box (SOX) transcription factor family, has been demonstrated to
be involved in tumorigenesis of many human malignancies; however, its role in primary gallbladder carcinoma
(PGC) is still largely unknown. The aim of this study was to investigate SOX4 expression in PGC and its prognostic
significance.
Methods: From 1997 to 2006, 136 patients underwent resection for PGC. The median follow-up was 12.8 months.
Immunostainings for SOX4 were performed on these archival tissues. The correlation of SOX4 expression with
clinicopathological features including survival was analyzed.
Results: SOX4 was expressed in 75.0% (102/136) of PGC but not in the normal epithelium of the gallbladder. In
addition, the over-expression of SOX4 was significantly associated with low histologic grade (P = 0.02), low
pathologic T stage (P = 0.02), and early clinical stage (P = 0.03). The levels of SOX4 immunostainings in PGC tissues
with positive nodal metastasis were also significantly lower than those without (P = 0.01). Moreover, Kaplan-Meier
curves showed that SOX4 over-expression was significantly related to better overall (P = 0.008) and disease-free
survival (P = 0.01). Furthermore, multivariate analyses showed that SOX4 expression was an independent risk factor
for both overall (P = 0.03, hazard ratio, 3.682) and disease-free survival (P = 0.04, hazard ratio, 2.215).
Conclusion: Our data indicate for the first time that the over-expression of SOX4 in PGC was significantly
correlated with favorable clinicopathologic features and was an independent prognostic factor for better overall
and disease-free survival in patients. Therefore, SOX4 might be an auxiliary parameter for predicting malignant
behavior for PGC.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1534825818694957.
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Introduction
Primary gallbladder carcinoma (PGC) is one of the most
common malignancies of the digestive tract in China. In
the last two decades, the diagnosis and therapeutic tech-
nologies have been greatly improved; however, the clini-
cal outcome of patients with PGC remains poor,
because of the early spread of tumors by lymphatic,
perineural and hematogenous routes and direct invasion
into the liver. There is no specific symptom for PGC
patients. So the diagnosis of this carcinoma is usually
made postoperatively on tumors at an advanced stage;
almost half of patients already have metastatic disease at
the time of surgery [1]. Similar with other various
human malignancies, multiple genetic or epigenetic
changes also contribute to the multistep process of
PGC, and some of these changes may help monitor this
multistep process [2]. Therefore, it is necessary to
understand the carcinogenic process and its correspond-
ing molecular basis for PGC, which may provide a use-
ful insight that aid in the evaluation of prognostic
factors, the establishment of new therapeutic strategies,
and the improvement of patients’ survival.
The SOX (sex-determining region Y-related high
mobility group [HMG] box) transcription factor family
* Correspondence: runzhe2003@yahoo.com.cn; du.xilintd@gmail.com
† Contributed equally
Department of general surgery, Tangdu Hospital, Fourth Military Medical
University, Xi’an 710038, People’s Republic of China
Wang et al. Diagnostic Pathology 2012, 7:41
http://www.diagnosticpathology.org/content/7/1/41
© 2012 Wang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.plays a key role in many aspects of development, includ-
ing sex determination, testis formation, neuronal devel-
opment, lymphocyte differentiation and chondrogenesis
[3]. Members in this family share the highly conserved
HMG box, which mediates binding of SOX proteins to
a short-target DNA sequence directly [4]. In vertebrates,
there have been more than 20 genes identified as mem-
bers of SOX family, and they have been categorized
into groups A-G according to their sequence similarity.
SOX4, one of group-C SOX genes, has been shown to
be involved in a range of developmental processes, such
as embryonic cardiac development, nervous system
development, osteoblastic differentiation, and thymocyte
development [5]. The SOX4 gene encodes a protein of
474 amino acids with three distinguishable domains: an
HMG box, a glycine-rich region and a serine-rich
region. The HMG box serves as a DNA-binding region,
whereas the serine-rich domain serves as a transactiva-
tion domain [6]. The central domain containing the gly-
cine-rich region located between the HMG box and
serine-rich domains serves as a novel functional region
for promoting apoptotic cell death [7]. Recently, it has
been demonstrated that SOX4 is involved in tumorigen-
esis of many human malignancies. The up-regulation of
SOX4 has been detected in breast cancer, pancreatic
cancer, lung cancer, prostate cancer, colon cancer,
meduloblastoma, ovarian cancer and hepatocellular car-
cinoma [8-12]. In addition, Aaboe et al. [13] found that
the strong SOX4 expression was correlated with
increased survival of patients with bladder cancer, and
it also impaired tumor cell viability and promoted apop-
tosis. Hur et al. [14] reported that SOX4 contributes to
hepatocarcinogenesis by inhibiting p53-mediated apop-
tosis and that its overexpression might be a useful prog-
nostic marker for better survival in patients with
hepatocellular carcinoma after surgical resection. How-
ever, its role in PGC is still largely unknown. To
address this problem, the aim of this study was to
investigate SOX4 expression in PGC and its prognostic
significance.
Materials and methods
Patients and tissue samples
The study was approved by the Research Ethics Com-
mittee of Department of general surgery, Tangdu Hospi-
tal, Fourth Military Medical University, Xi’an, P.R.
China. Informed consent was obtained from all of the
patients. All specimens were handled and made anon-
ymous according to the ethical and legal standards.
Prospectively collected data of 136 patients (60 men
and 76 women), who underwent surgery for PGC
between November 1997 and November 2006, were
reviewed. The mean age of the patients was 66 years
(range, 30-87 years). A curative resection (R0) was
defined as negative resection margins by light microsco-
pical examination. For each patient prospectively regis-
tered clinicopathological variables were extracted from
the electronic clinical records: demographic data (age,
gender), presenting symptoms, biochemistry, and surgi-
cal therapy. All the pathology slides were reviewed by
two pathologists with special attention for tumor growth
pattern and differentiation, the pathologic margin status,
the presence of lymphovascular invasion, perineural
invasion and the total number and status of regional
and distant lymph nodes harvested. Tumor stage was
classified according to the American Joint Committee
on Cancer system. For histologic grading, the PGC spe-
cimens were examined by routine hematoxylin and
eosin staining. The specimens were graded into well
(G1), moderately (G2), poorly differentiated (G3), and
undifferentiated (G4) adenocarcinoma according to the
World Health Organization classification. The clinico-
pathological features of the patients are summarized in
Table 1.
Follow-up data were recorded from the patient’s medi-
cal records and completed by a telephone survey per-
formed on July 2011. Overall survival (OS) was defined
a st h et i m e( m o n t h s )f r o mt h ed a t eo fs u r g e r yt ot h e
date of death by PGC. Disease-free survival (DFS) was
defined as the time (months) from the date of surgery
to the date of the first recurrence confirmed by imaging
modalities. Median post-operative follow-up was 12.8
months (range: 22 days ~ 126.3 months). During the fol-
low-up period, thirty-two patients (23.5%) were still
alive, but 104 patients (76.5%) died. The overall mean ±
SEM survival time of the 136 patients was 29.6 ± 1.8
months. There was no perioperative mortality.
Immunohistochemical staining and assessment
For immunohistochemical staining, formalin-fixed paraf-
fin-embedded tissue was cut into 4-μm sections. Com-
mercially available mouse-antihuman monoclonal
antibody against SOX4 (1:100 dilution; American
Research Products, Belmont, Mass) was used. The speci-
ficity of the primary antibody against SOX4 has been
demonstrated by the previous study of Shen et al. [15].
Immunohistochemical staining was carried out on sec-
tions using the avidin-biotin method and a commercially
available kit (Vectastain Elite ABC kit, Vector Labora-
tories, Burlingame, CA). Deparaffinized sections were
treated with methanol containing 3% hydrogen peroxide
for 10 min before conducting antigen retrieval using a
microwave oven at 95°C for 5 min and cooling at 25°C
f o r2h .A f t e rw a s h i n gw i t hP B S ,b l o c k i n gs e r u mw a s
applied for 10 min. The sections were incubated with
anti-SOX4 monoclonal antibody overnight at 4°C. After
washing in PBS, a biotin-marked goat anti-mouse sec-
ondary antibody was applied for 10 min followed by a
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min. The reaction was visualized by using 3, 3’-diamino-
benzidine tetrahydrochloride. The nuclei were counter-
stained with hematoxylin. Positive and negative
immunohistochemistry controls were routinely used.
Reproducibility of staining was confirmed by reimmu-
nostaining via the same method in multiple, randomly
selected specimens.
Immunoreactivity was assessed by two investigators
who were blinded to clinicopathologic data. Discrepan-
cies were resolved by simultaneous reexamination of the
slides by both investigators using a double-headed
microscope. Scoring of immunohistochemistry was
based on two parameters: the proportion of immunopo-
sitive cells and their intensity of immunoreactivity. The
proportion of immunopositive cells was categorized as
follows: 0: < 10%; 1: ≥ 10% to < 25%; 2: ≥ 25% to < 50%;
3: ≥ 50% to < 75% and 4: ≥ 75%. The staining intensity
was categorized by relative intensity as follows: 0: no
positivity; 1: weak; 2: moderate and 3: strong. A final
immunoreactivity score of each section was obtained by
multiplying the two individual scores and was divided
into four levels: ‘0’, negative; ‘1~4 ’,w e a k ;‘5~8 ’,m o d -
erate; ‘9~1 2 ’, strong.
Table 1 Association of SOX4 expression with the clinicopathological features of 136 patients with PGC
Factor NO. SOX4 expression (n, %) P
Negative Weak Moderate Strong
Gender
Male 60 14 (23.3) 9 (15.0) 20 (33.3) 17 (28.3) NS
Female 76 20 (22.2) 12 (15.8) 25 (32.9) 19 (25.0)
Age
≤ 66 years 65 16 (24.6) 10 (15.4) 21 (32.3) 18 (27.7) NS
> 66 years 71 18 (25.4) 11 (15.5) 24 (33.8) 18 (25.4)
Tumor size
≤ 2.5 cm 72 19 (26.4) 12 (16.7) 25 (34.7) 16 (22.2) NS
> 2.5 cm 64 15 (23.4) 9 (14.1) 20 (31.3) 20 (31.3)
Histological grade
G1 18 1 (5.6) 3 (16.7) 4 (22.2) 10 (55.6) 0.02
G2 72 13 (18.1) 3 (4.2) 32 (44.4) 24 (33.3)
G3 33 10 (30.3) 13 (39.4) 8 (24.2) 2 (6.1)
G4 13 10 (76.9) 2 (15.4) 1 (7.7) 0 (0.0)
Pathologic T stage
T1 22 2 (9.1) 2 (9.1) 6 (27.3) 12 (54.5) 0.02
T2 60 4 (6.7) 5 (8.3) 29 (48.3) 22 (36.7)
T3 36 16 (44.4) 10 (27.8) 8 (22.2) 2 (5.6)
T4 18 12 (66.7) 4 (22.2) 2 (11.1) 0 (0.0)
Clinical stage
I 46 4 (8.7) 6 (13.0) 16 (2.2) 20 (43.5) 0.03
II 52 8 (15.4) 4 (7.7) 25 (48.1) 15 (28.8)
III 18 10 (55.6) 5 (27.8) 2 (11.1) 1 (5.6)
IV 20 12(60.0) 6 (30.0) 2 (10.0) 0 (0.0)
Nodal metastasis
Negative 92 12 (13.0) 3 (3.3) 41 (44.6) 36 (39.1) 0.01
Positive 44 22 (50.0) 18 (40.9) 4 (9.1) 0 (0.0)
Distant metastasis
Negative 112 28 (25.0) 16 (14.3) 35 (31.3) 33 (29.5) NS
Positive 24 6 (25.0) 5 (20.8) 10 (41.7) 3 (12.5)
Venous/lymphatic invasion
Negative 82 22 (26.8) 12 (14.6) 24 (29.3) 24 (29.3) NS
Positive 54 12 (22.2) 9 (16.7) 21 (38.9) 12 (22.2)
Perineural invasion
Negative 79 20 (25.3) 12 (15.2) 24 (30.4) 23 (29.1) NS
Positive 57 14 (24.6) 9 (15.8) 21 (36.8) 13 (22.8)
Note: ’NS’ refers to ‘No statistic significance’
Wang et al. Diagnostic Pathology 2012, 7:41
http://www.diagnosticpathology.org/content/7/1/41
Page 3 of 7Statistical analysis
SPSS13.0 software for Windows (SPSS Inc, USA) was
used for statistical analysis. Continuous variables were
expressed as X ± s. Group comparisons of categorical
variables were evaluated using the Fisher’se x a c to r
Pearson’s chi-square test. Kaplan-Meier method was
used for the question of survival. Chiquest trend test
and Cox regression analysis were performed for ordinal
datum and the multivariate analysis, respectively. The p
values of less than 0.05 were considered to be statisti-
cally significant.
Results
Immunohistochemical findings of SOX4 in PGC
To assess the biological significance of SOX4 expression
in gallbladder tumors, we evaluated its expression in
136 PGC samples from PGC patients with full clinical
annotation. As the results, the expression of SOX4 was
observed in both cell nucleus and cytoplasm of tumor
cells in PGC samples (Figure 1A) which was consistent
with previous studies [11,12], and varied in intensity and
extent of staining in different tumors. SOX4 expression
was not detected in the normal epithelium of the gall-
bladder (Figure 1B). In addition, SOX4 was expressed in
75.0% (102/136) tumor samples and was strongly
expressed in 36 (26.5%), moderately expressed in 45
(33.1%), and weakly expressed in 21 (15.4%), and not
expressed in 34 (25.0%) tumor samples.
Association between SOX4 expression and the
clinicopathological features of PGC
Various clinicopathological features of PGC patients and
their tumors were compared based on the expression
levels of SOX4 they had. The analysis revealed that the
tumors with strong SOX4 expression less frequently
showed positive nodal metastasis (P = 0.01). The tumors
with the over-expression of SOX4 tended to show low
histologic grade (P = 0.02), low pathologic T stage (P =
0.02), and early clinical stage (P = 0.03). There was no
significant association with age, gender, or tumor size
(Table 1).
Prognostic value of SOX4 expression in PGC
Adequate clinical follow-up information was available
for all 136 cases. We investigated the prognostic value
of SOX4 expression in PGC. The OS rates of SOX4
negative and SOX4 positive (weak ~ strong) were 11.8%
and 45.1%, respectively (P < 0.001), and the DFS rate of
SOX4 negative and SOX4 positive (weak ~ strong) was
14.7% and 49.0%, respectively (P < 0.001). The survival
curves according to SOX4 expression are shown in Fig-
ure 2. The analysis with Kaplan-Meier method clearly
showed that PGC patients having tumors with strong
SOX4 expression had respectively increased OS and
DFS compared with patients with negative, weak or
moderate SOX4 expression (P = 0.008 and 0.01, Figure
2A and 2B, respectively).
Then, we estimated the clinical significance of various
prognostic factors that might influence survival and
recurrence. As summarized in Table 2, the univariate
analysis suggested that advanced pathologic T stage (P =
0.008), advanced clinical stage (P < 0.001), nodal metas-
tasis (P = 0.001), distant metastasis (P = 0.001), and
negative SOX4 expression (P = 0.01) were statistically
significant risk factors affecting OS of patients with
PGC. In case of DFS, advanced pathologic T stage (P =
0.02), advanced clinical stage (P = 0.001), nodal metasta-
sis (P = 0.001), and negative SOX4 expression (P = 0.02)
were statistically significant risk factors.
Furthermore, we evaluated the independent prognostic
impacts of these various factors. As summarized in
Table 3, the multivariate analysis using the Cox
Figure 1 Immunohistochemical staining of SOX4 expression in
PGC. Commercially available mouse-antihuman monoclonal
antibody against SOX4 was used to stain the paraffin section. A,
Strong cytoplasmic and nuclear expression of SOX4 was detected at
the tumor cells of PGC tissues (original magnification × 400); B,
SOX4 was negative in normal epithelium of gallbladder (original
magnification × 400).
Figure 2 Overall survival (A) and disease-free survival (B) in
136 patients with PGC according to the expression levels of
SOX4. The analysis with Kaplan-Meier method clearly showed that
PGC patients having tumors with strong SOX4 expression (+++) had
respectively increased overall (P = 0.008) and DFS (P = 0.01)
compared with patients with negative (-), weak (+) or moderate (+
+) SOX4 expression.
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cal stage (hazard ratio [HR], 8.862; 95% confidence
interval [CI], 1.328-26.523; P =0 . 0 0 8 )a n dnegative
SOX4 expression (HR, 3.682; 95% CI, 1.102-10.282; P =
0.03) were independent risk factors predicting short OS.
In case of DFS, advanced clinical stage (HR, 3.391; 95%
CI, 1.183-9.923; P = 0.02) and negative SOX4 expression
(HR, 2.215; 95%CI, 1.088-7.016; P = 0.04) were indepen-
dent risk factors predicting short DFS (Table 3).
Discussion
PGC is an aggressive and lethal cancer. Patients with
this carcinoma are usually treated at an advanced stage,
and the prognosis remains poor despite the develop-
ment of modern diagnostic methods. Therefore, it is
necessary to understand the mechanisms responsible for
the characteristic growth and metastasis of PGC. In the
present study, the immunohistochemical expression of
the SOX4 protein in a large number of PGC was ana-
lyzed. There are four points of our findings. Firstly, the
SOX4 protein was up-regulated in tumor cells of PGC
tissues, but not expressed in normal epithelium of gall-
bladder; Secondly, the decreased SOX4 expression in
PGC tissues was significantly correlated with advanced
tumor progression and aggressive clinicopathological
features; Thirdly, the results of Kaplan-Meier analyses
shown that PGC tissues with strong SOX4 expression
tend to have increased OS and DFS rates respectively.
Finally, both univariate and multivariate analyses clearly
demonstrated that the negative SOX4 expression was a
statistically significant risk factor affecting OS and DFS
of patients with PGC, suggesting that SOX4 expression
could be a useful marker to predict patient survival.
The SOX4 gene, localized to 6p22.3, is highly con-
served in vertebrates [16]. It has 88% identity at the
DNA level between Homo sapiens and Fugu rubripes in
the NH2-terminal domain [17]. The SOX4 gene encodes
a 47 kDa protein of the SOX family, which may play
roles in the development of cancer cells. For one thing,
SOX4 has been demonstrated as a tumor suppressor
gene. For example, Aaboe et al. [13] in 2006 reported
that the overexpression of SOX4 in bladder carcinoma
cell lines could strongly impaired cell viability and pro-
moted apoptosis. They also found a correlation between
strong SOX4 expression and increased survival in
patients with bladder carcinoma. Pan et al. [18] in 2009
Table 2 Univariate analysis of the association between prognosis and various clinicopathologic parameters in patients
with PGC
Features Overall survival Disease-free survival
Hazard ratio 95% CI P Hazard ratio 95% CI P
Gender (Male vs. Female) 0.672 0.328-1.296 NS 1.007 0.426-2.335 NS
Age (≤ 66 years vs.≥ 66 years) 0.766 0.357-1.402 NS 0.890 0.368-1.563 NS
Tumor size (≤ 2.5 cm vs.≥ 2.5 cm) 0.819 0.334-1.628 NS 1.023 0.269-2.682 NS
Histological grade (G1-G2 vs. G3± G4) 0.981 0.365-2.879 NS 1.107 0.319-2.989 NS
Pathologic T stage (T1± T2 vs. T3 ± T4) 3.387 1.528-8.336 0.008 3.072 1.269-8.668 0.02
Clinical stage (I± II vs. III ± IV) 5.620 1.591-11.072 < 0.001 4.863 1.893-10.651 0.001
Nodal metastasis (Negative vs. Positive) 4.701 1.310-8.543 0.001 4.663 1.700-10.253 0.001
Distant metastasis (Negative vs. Positive) 4.509 1.271-9.775 0.001 2.181 1.037-4.357 NS
Venous/lymphatic invasion (Negative vs. Positive) 2.687 1.190-5.053 NS 2.508 1.431-4.383 NS
Perineural invasion (Negative vs. Positive) 1.216 1.087-3.126 NS 1.246 1.507-3.608 NS
SOX4 expression (Negative vs. Positive) 3.237 1.221-7.952 0.01 3.782 1.339-8.862 0.02
Note: ’NS’ refers to ‘No statistic significance’
Table 3 Multivariate analysis of the association between prognosis and various clinicopathologic parameters in
patients with PGC
Features Overall survival Disease-free survival
Hazard ratio 95% CI P Hazard ratio 95% CI P
Pathologic T stage (T1± T2 vs. T3 ± T4) 0.528 0.106-5.291 NS 1.066 0.281-6.893 NS
Clinical stage (I± II vs. III ± IV) 8.862 1.328-26.523 0.008 3.391 1.183-9.923 0.02
Nodal metastasis (Negative vs. Positive) 1.728 0.553-6.965 NS 1.625 0.685-7.097 NS
Distant metastasis (Negative vs. Positive) 1.763 1.128-6.553 NS 1.711 0.737-7.267 NS
Venous/lymphatic invasion (Negative vs. Positive) 2.181 1.018-8.106 NS 2.527 1.023-8.298 NS
Perineural invasion (Negative vs. Positive) 0.826 0.115-3.089 NS 0.908 0.259-3.765 NS
SOX4 expression (Negative vs. Positive) 3.682 1.102-10.282 0.03 2.215 1.088-7.016 0.04
Note: ’NS’ refers to ‘No statistic significance’
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required for the activation of p53 tumor suppressor in
response to DNA damage. It interacts with and stabi-
lizes p53 protein by blocking Mdm2-mediated p53 ubi-
quitination and degradation, and also enhances p53
acetylation by interacting with p300/CBP and facilitating
p300/CBP/p53 complex formation. Consequently, SOX4
promotes cell cycle arrest and apoptosis, and it inhibits
tumorigenesis in a p53-dependent manner. In 2010, Hur
et al. [14] further demonstrated that SOX4 interacts
with p53 using its HMG box domain, which leads to the
inhibition of p53-mediated transcription by the Bax pro-
moter. In clinicopathological analysis, they also indicated
that the nuclear overexpression of SOX4 was observed
in tumor cells of hepatocellular carcinoma tissues,
which was correlated with diminished risk of recurrence
and improved overall survival time in patients. For the
other thing, SOX4 also acts as an oncogene in some
tumors. For example, Chen et al. [19] in 2007 found
that SOX4 gene mutation is significantly associated with
pathological stages and the mutation rate increases gra-
dually, which has relation with advanced pathological
stages in non-small cell lung cancer tissues, suggesting
that the SOX4 gene mutations might be related in the
lung carcinogenesis and tumor metastasis. In 2009,
Medina et al. [20] emphasize the oncogenic properties
of SOX4 and show the interaction between gene ampli-
fication at 6p and SOX4 overexpression in lung cancer.
Therefore, whether SOX4 may act as a tumor suppres-
sor or an oncogene seems to be determined by the func-
tion of its interactors and the signal transduction it is
involved in. Consistent with the findings of Aaboe et al.
[13] in bladder carcinoma and Hur et al. [14] in hepato-
cellular carcinoma, our data shown that the expression
levels of SOX4 in moderately or poorly differentiated
PGC was significantly lower than that in well-differen-
tiated PGC. The decreased expression of SOX4 was also
significantly associated with advanced pathologic T
stage, advanced clinical stage, and positive nodal metas-
tasis, suggesting that SOX4 expression might be of clini-
cal relevance in the aggressiveness of PGC. We further
demonstrated that the SOX4 expression was associated
with a favorable outcome in patients with PGC.
In conclusion, our data have provided evidence for the
first time that the SOX4 protein is highly up-regulated in
tumor cells of PGC tissues. We have shown that strong
SOX4 protein expression is correlated with less agressive
clinicopathological features and increased patient survi-
val. Therefore, SOX4 might be an auxiliary parameter for
predicting malignant behavior for PGC. However, the
precise mechanism that SOX4 is involved in the tumori-
gensis and tumor progression of PGC remains unclear.
The further prospective analysis would be worth doing.
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